PITTSBURGH, June 30 Precision Therapeutics, a life-science company known for their expertise in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, continues to gain ground in novel genomic testing and bioinformatics research.
Precision Therapeutics has recently recruited key scientific research experts, biostatisticians and medical specialists to support their development efforts. "I think Precision is addressing a very important clinical question, using a unique scientific approach that holds high potential to realizing personalized medicine," states Shuguang Huang, Ph.D., newly appointed Director of Bioinformatics at Precision. Huang is the former Director of Discovery Biostatistics and Translational Medicine for Wyeth Research, and was previously a Senior Research Scientist for Eli Lilly and Co.
It is Precision's dedication to ongoing research and clinical trials that has attracted top-level physicians and research scientists. Chunqiao Tian, Ph.D., was also recruited to join the company as the Director of Biostatistics. "I came to Precision because I believe that individualized therapy is the future of cancer treatment, and this company plays a leading role in that field," states Dr. Tian. Tian was an International Visiting Scholar and leading biostatistician with the Gynecologic Oncology Group (GOG), a non-profit clinical and scientific research organization in the field of gynecologic malignancies.
The clinical trials team at Precision has been augmented with the addition of Hong Ma, M.D., a medical oncologist and expert in Phase I-IV clinical trials. Dr. Ma comes to Precision with 16 years of experience in clinical trials with a focus in oncology, medical devices and drug development.
Precision is actively developing multi-genomic predictors of patient response to cancer therapy. State-of-the-art bioinformatics combined with the company's proprietary live tissue platform provides a unique foundation and methodology for development and commercialization of these novel predictive markers for cancer therapy. Early validation data presented at AACR 2010 shows promising results for novel multi-gene predictors currently in development.
Precision's first commercial test, ChemoFx(Ū), is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. ChemoFx(Ū) has shown positive outcomes in patient survival rates while significantly lowering healthcare costs when a physician chooses a therapy deemed responsive by the marker.
Precision Therapeutics, led by CEO Sean McDonald, has tripled its number of employees in a little over 3 years, and plans to open a second clinical laboratory in the Lawrenceville sector of Pittsburgh in July, 2010.
For more information, please visit www.precisiontherapeutics.com or www.chemofx.com.
SOURCE Precision Therapeutics, Inc.